The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
Author(s): Karonen T, Neuvonen PJ, Backman JT
Affiliation(s): Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, P.O. Box 705, 00029 HUS, Helsinki, Finland.
Publication date & source: 2011-02, Eur J Clin Pharmacol., 67(2):151-5. Epub 2010 Oct 8.
Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't
PURPOSE: Gemfibrozil, a strong inhibitor of cytochrome P450 (CYP) 2C8 in vivo, was recently found to markedly increase the plasma concentrations of montelukast in humans. Like montelukast, zafirlukast is a substrate of CYP2C9 and CYP3A4 and a potent inhibitor of CYP2C8 in vitro. To investigate the contribution of CYP2C8 to the metabolism of zafirlukast in vivo, we studied the effect of gemfibrozil on the pharmacokinetics of zafirlukast. METHODS: Ten healthy subjects in a randomized cross-over study took gemfibrozil 600 mg or placebo twice daily for 5 days, and on day 3, a single oral dose of 20 mg zafirlukast. The plasma concentrations of zafirlukast were measured for 72 h postdose. RESULTS: The mean total area under the plasma concentration-time curve of zafirlukast during the gemfibrozil phase was 102% (geometric mean ratio; 95% confidence interval 89-116%) of that during the placebo phase. Furthermore, there were no statistically significant differences in the peak plasma concentration, time of peak concentration, or elimination half-life of zafirlukast between the phases. CONCLUSIONS: Gemfibrozil has no effect on the pharmacokinetics of zafirlukast, indicating that CYP2C8 does not play a significant role in the elimination of zafirlukast.